Kyle Scranton

Kyle Scranton

Auto-generated profile, based on publicly available information

Kyle Scranton

Division of Molecular Medicine, Department of Anesthesiology & Perioperative Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKyle Scranton
Kyle Scranton
SJScott John
Scott John
MAMarina Angelini
Marina Angelini
FSFederica Steccanella
Federica Steccanella
SUSoban Umar
Soban Umar
MOMichela Ottolia
Michela Ottolia
The Na+-Ca2+ exchanger (NCX1) is the dominant Ca2+ extrusion mechanism in cardiac myocytes. NCX1 activity is inhibited by intracellular Na+ via a process known as Na+-dependent inactivation. A central question is whether this inactivation plays a physiological role in heart function. Using CRISPR/Cas9, we inserted the K229Q mutation in the gene (Slc8a1) encoding for NCX1. This mutation removes the Na+-dependent inactivation while preserving transport properties and other allosteric regulations. NCX1 mRNA levels, protein expression, and protein localization are unchanged in K229Q male mice. However, they exhibit reduced left ventricular ejection fraction and fractional shortening, while displaying a prolonged QT interval. K229Q ventricular myocytes show enhanced NCX1 activity, resulting in action potential prolongation, higher incidence of aberrant action potentials, a faster decline of Ca2+ transients, and depressed cell shortening. The results demonstrate that NCX1 Na+-dependent inactivation plays an essential role in heart function by affecting both cardiac excitability and contractility.

19 December 2025 in Science Advances
Verified
Journal Article
Open access
KSKyle Scranton
Kyle Scranton
SJScott John
Scott John
MAMarina Angelini
Marina Angelini
RZRui Zhang
Rui Zhang
ASAndreas Schwingshackl
Andreas Schwingshackl
MOMichela Ottolia
Michela Ottolia
For more than two centuries, digoxin has been used to treat heart failure by increasing the strength of cardiac contraction and, more recently, is used for heart rate control. The proposed, yet unproven, mechanism underlying digoxin’s positive inotropic effect is as follows: By inhibiting the Na + -K + ATPase (NKA), digoxin partially dissipates the transmembrane Na + gradient, which is used by the Na + -Ca 2+ exchanger (NCX1) to extrude Ca 2+ from myocytes, thus causing accumulation of cytosolic Ca 2+ and therefore increased cardiac contractility. Here, we demonstrate that digoxin critically relies on a specific allosteric regulation of NCX1, known as Na + -dependent inactivation, to exert its positive inotropic effect, establishing the precise mechanism of action of this historic drug. These findings identify a distinct molecular target for the development of positive inotropes that avoid the undesirable effects associated with the blockade of NKA. As the structural information for the region involved with NCX1 Na + -dependent inhibition is well resolved, we provide the mechanistic foundation for drug development.

1 February 2020 in Biophysical Journal
Verified
Journal Article
Closed access
PDF file
KSKyle Scranton
Kyle Scranton
SUSoban Umar
Soban Umar
GCGuillaume Calmettes
Guillaume Calmettes
MEMansoureh Eghbali
Mansoureh Eghbali
JGJoshua I. Goldhaber
Joshua I. Goldhaber
MOMichela Ottolia
Michela Ottolia

1 February 2020 in Biophysical Journal
Verified
Journal Article
Closed access
PDF file
FSFederica Steccanella
Federica Steccanella
KSKyle Scranton
Kyle Scranton
NPNamuna Panday
Namuna Panday
MAMarina Angelini
Marina Angelini
RZRui Zhang
Rui Zhang
MOMichela Ottolia
Michela Ottolia

16 May 2026 in Nature Communications
Verified
Journal Article
Open access
MAMarina Angelini
Marina Angelini
MMMoira McVicar
Moira McVicar
SMSavana Maxfield
Savana Maxfield
MSMilosz Sokolowski
Milosz Sokolowski
SNSanjana Narang
Sanjana Narang
RORiccardo Olcese
Riccardo Olcese
Low-voltage-activated (LVA, T-type, or Ca V 3), calcium-selective channels open in response to modest depolarizations, just above the resting membrane potential, supporting neuronal burst-firing patterns and spontaneous firing in cardiac pacemaker cells. How LVA-channels open at low voltages is unclear: traditional gating-current experiments suggest that LVA-channel voltage-sensing domains (VSDs) paradoxically require stronger depolarization to activate than pore opening. Using voltage-clamp fluorometry, we find that the activation of all four VSDs in human Ca V 3.1-channels precedes opening in voltage, solving the longstanding conundrum. We also uncover confounding effects of La 3+ (used for gating-current measurements) on VSD function and clarify the role of distinct LVA-channel structure S6 Cyto . Ca V 3.1-VSDs operate within a narrow voltage-range, resembling the VSDs of related Na V -channels more than those of other Ca V -channels. Likely, Na V -like VSDs emerge before sodium selectivity.